E-Mail
An experimental treatment can essentially reverse type 1 diabetes in certain types of laboratory mice, according to a series of studies led by University of Utah Health scientists. An injection of the therapeutic agent converts cells that normally control glucose production into ones that generate insulin.
The researchers say giving the animals a single dose of a human antibody that suppress the actions of glucagon, a hormone involved in glucose regulation, sparked a remarkable transformation in the pancreas, leading to a nearly 7-fold increase in insulin cell mass and the suppression of diabetic symptoms. These animals go from requiring insulin injections to never requiring a diabetes treatment again. They maintain normal blood glucose long after we stop the treatment, says William L. Holland, Ph.D., the study s corresponding author and a U of U Health assistant professor of Nutrition and Integrative Physiology. What this implies for millions of people who have type
By TARA COPP | McClatchy Washington Bureau | Published: February 18, 2021 WASHINGTON (Tribune News Service) Depleted uranium in tanks and ammunition used in the 1991 Gulf War “played no role” in the unexplained illnesses, known as Gulf War syndrome, that veterans faced in the years afterward, according to a new study. The findings by the University of Texas Southwestern Medical Center and the University of Portsmouth in England counter decades of understanding by the military and Department of Veterans Affairs about potential causes for a host of ailments that collectively are now known as Gulf War illness. “That depleted uranium is not and never was in the bodies of those who were ill at sufficient quantities to cause disease will surprise many, including sufferers who have, over the last 30 years, suspected depleted uranium may have contributed to their illnesses,” said Randall Parrish, a uranium isotope expert at the University of Portsmouth who developed the study
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at .
Clene Inc.February 19, 2021 GMT
SALT LAKE CITY, Feb. 19, 2021 (GLOBE NEWSWIRE) Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced that it will present updated interim data from its REPAIR-MS study and updated blinded interim data from its VISIONARY-MS study in poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis’ ACTRIMS Forum 2021 (“ACTRIMS”) taking place virtually from February 25-27, 2021.
Gulf War syndrome likely caused by sarin nerve gas not depleted uranium munitions, study finds iwradio.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iwradio.co.uk Daily Mail and Mail on Sunday newspapers.